on August 12, 2004
Published online before print August 12, 2004, doi: 10.1161/01.ATV.0000142363.15113.88
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 29, 2003
Accepted on July 30, 2004
Endothelium-Targeted Gene and Cell-Based Therapies for Cardiovascular Disease
Luis G. Melo *;
From the Department of Physiology (L.G.M., K.W., X.L.), Queen’s University, Kingston, Ontario, Canada; and the Department of Medicine (L.G.M., M.G., A.S.P., D.K., R.E.P., V.J.D.), Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass.
* To whom correspondence should be addressed. E-mail: melol{at}post.queensu.ca.
Abstract--Most common cardiovascular diseases are accompanied by endothelial dysfunction. Because of its predominant role in the pathogenesis of cardiovascular disease, the vascular endothelium is an attractive therapeutic target. The identification of promoter sequences capable of rendering endothelial-specific transgene expression together with the recent development of vectors with enhanced tropism for endothelium may offer opportunities for the design of new strategies for modulation of endothelial function. Such strategies may be useful in the treatment of chronic diseases such as hypertension, atherosclerosis, and ischemic artery disease, as well as in acute myocardial infarction and during open heart surgery for prevention of ischemia and reperfusion (I/R)-induced injury. The recent identification of putative endothelial progenitor cells in peripheral blood may allow the design of autologous cell-based strategies for neovascularization of ischemic tissues and for the repair of injured blood vessels and bioengineering of vascular prosthesis. "Proof-of-concept" for some of these strategies has been established in animal models of cardiovascular disease. However the successful translation of these novel strategies into clinical application will require further developments in vector and delivery technologies. Further characterization of the processes involved in mobilization, migration, homing, and incorporation of endothelial progenitor cells into the target tissues is necessary, and the optimal conditions for therapeutic application of these cells need to be defined and standardized.
This article has been cited by other articles:
 |
|
 |
|
  H. Froehlich, R. Gulati, B. Boilson, T. Witt, A. Harbuzariu, L. Kleppe, A. B. Dietz, A. Lerman, and R. D. Simari Carotid Repair Using Autologous Adipose-Derived Endothelial Cells Stroke, May 1, 2009; 40(5): 1886 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Hecht, J. Rong, A. L. F. Sampaio, C. Hermesh, C. Rutledge, R. Shemesh, A. Toporik, M. Beiman, L. Dassa, H. Niv, et al. A Novel Peptide Agonist of Formyl-Peptide Receptor-Like 1 (ALX) Displays Anti-Inflammatory and Cardioprotective Effects J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 426 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Deckers, B. Quesson, J. Arsaut, S. Eimer, F. Couillaud, and C. T. W. Moonen Image-guided, noninvasive, spatiotemporal control of gene expression PNAS, January 27, 2009; 106(4): 1175 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-L. Levonen, E. Vahakangas, J. K. Koponen, and S. Yla-Herttuala Antioxidant Gene Therapy for Cardiovascular Disease: Current Status and Future Perspectives Circulation, April 22, 2008; 117(16): 2142 - 2150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Khurana, M. Simons, J. F. Martin, and I. C. Zachary Role of Angiogenesis in Cardiovascular Disease: A Critical Appraisal Circulation, September 20, 2005; 112(12): 1813 - 1824. [Abstract] [Full Text] [PDF]
|
|